RxDoctor Payments Data

Julia Becker, MD

Critical Care Medicine · Grand Rapids, MINPI 1902969546

Payments from drug & device makers

$337in general payments, 2019–2025

Across 16 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$70
  • Sanofi$63
  • Sanofi-aventis U.S. LLC$57
  • Regeneron Healthcare Solutions, Inc.$22
  • CSL Behring$19
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$19
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$26077%
  • Education$7723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$337 in reported general payments places this provider in the 45th percentile of 177 critical care medicine providers in Michigan.

See all critical care medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$49,378
Medicare patients
327
Services billed
673

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate73$887,144
Trelegy ElliptaFluticasone/Umeclidin/Vilanter294$367,986
Breztri AerosphereBudesonide/Glycopyr/Formoterol125$132,730
Spiriva RespimatTiotropium Bromide99$87,780
Stiolto RespimatTiotropium Br/Olodaterol Hcl42$42,947
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate102$34,254
Fluticasone-SalmeterolFluticasone Propion/Salmeterol97$29,300
DuleraMometasone/Formoterol50$24,477
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$23,794
SymbicortBudesonide/Formoterol Fumarate56$22,877
Advair HfaFluticasone Propion/Salmeterol40$17,755
XareltoRivaroxaban11$17,425
Breo ElliptaFluticasone/Vilanterol17$13,533
Albuterol Sulfate HfaAlbuterol Sulfate238$13,301
Incruse ElliptaUmeclidinium Bromide21$9,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$18$1,017,871214 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$70$414,697355 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 177 critical care medicine providers in Michigan.

Other critical care medicine in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →